Lupin inks pact with TTP plc UK for Soft-mist Inhalation Technology Platform

With this collaboration, Lupin hopes to provide healthcare professionals alternative solutions for affordable inhaled medicines to patients across the world.

Lupin Ltd, a leading pharmaceutical company announced this morning that Lupin Inc., a wholly-owned subsidiary of global pharma major has signed an agreement with TTP plc (The Technology Partnership plc) for the acquisition of exclusive worldwide rights to develop, manufacture and commercialize inhalation products using TTP's soft-mist inhalation (SMI) technology platform.

The soft-mist inhalation (SMI) technology makes use of a small, portable hand-held inhaler device that release inhalation drugs in a fine mist using a precisely engineered nozzle system to produce a slow-moving aerosol cloud that lasts longer in the air. Also, these inhalers are propellant-free. Lupin anticipates applications across respiratory care.

As per the agreement, both the companies, Lupin and TTP plc shall work together to develop the device. In this collaboration, Lupin will undertake commercial production of the device and make use of its network of in-house and external manufacturing locations for the same. Moreover, the pharma major will also develop and manufacture formulations to be delivered through the device, procure the pre-requisite regulatory approvals, and commercialize the products globally.

In Q2FY22, on a consolidated basis, Lupin reported a revenue of Rs 4003.42 crore. The pharma company operates in the cardiovascular, anti-diabetic, and respiratory segments and has a strong presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. It has 15 manufacturing sites, seven research centres, and more than 20,000 professionals in its global workforce.

At 1.50 pm, the share price of Lupin Ltd was trading at Rs 871.75, which was an increase of 0.06% from the previous day’s closing price of Rs 871.25 on BSE.